AmoyDx Collaborates with AstraZeneca to Develop a HER2 Companion Diagnostic for Lung Cancer in China
We are thrilled to announce that AmoyDx reaches a new collaboration agreement with AstraZeneca. Under this agreement, the AmoyDx® Essential NGS panel will be used as a companion diagnostic of ENHERTU® to identify HER2 (ERBB2) mutations in patients with no
AmoyDx Signed a Collaboration Agreement with AstraZeneca for HRD Companion Diagnostic
Amoy Diagnostics Co., Ltd (AmoyDx), a China-based innovative molecular diagnostics company (SZSE: 300685), announced that it has entered into a Companion Diagnostic Collaboration Agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical
Meet our team at 2023 ASCO Annual Meeting in Chicago, June 2-6
Amoydx will be attending the 2023 ASCO Annual meeting held in Chicago, IL from June 2-6.
Visit us at PrecisionMed Exhibition and Summit 2023
We will be attending the PrecisionMed Exhibition and Summit 2023 at Dubai World Trade Center from May 23-24.
AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for selpercatinib RET fusion positive NSCLC
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) as a companion diagnostic for RET fusion-positive non-small cell lung cancer (“NSCLC”), for selpercatinib capsules 40 mg
AmoyDx will be attending the 2023 AACR Annual Meeting in Florida
Say hello to us at booth 1220 and learn more about our companion diagnostic solutions.